Is Sermorelin Legal in Ohio?

The Short Answer on Ohio Legality

Sermorelin is legal in Ohio. A licensed prescriber can write a prescription, and a licensed compounding pharmacy can fill it. Ohio has not enacted any state-level ban or scheduling of sermorelin, and the peptide does not appear on the DEA's list of controlled substances. The governing framework is almost entirely federal, flowing from FDA regulations on compounded drugs and the Drug Quality and Security Act of 2013.

Understanding why requires a short tour through federal compounding law, the FDA's "bulk drug substances" lists, and how Ohio's own pharmacy board aligns with those federal standards.

Federal Framework: Why FDA Rules Dominate

The 2008 Withdrawal of Geref

Sermorelin acetate was once FDA-approved under the brand name Geref (Serono), indicated for idiopathic growth hormone deficiency in children. Serono voluntarily withdrew Geref from the U.S. Market in 2008 for commercial reasons, not for safety findings [1]. That withdrawal is the origin of most legal confusion: sermorelin lost its approved-drug status, which changed how compounding pharmacies may legally handle it.

What "Voluntarily Withdrawn" Means for Compounders

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits licensed pharmacies to compound drugs for individual patients provided, among other conditions, the drug is not "essentially a copy" of a commercially available product and is not on the FDA's list of drugs withdrawn for safety or efficacy reasons [2]. Because Geref was withdrawn for commercial reasons only, sermorelin does not appear on the FDA's "withdrawn for safety" list. That distinction matters: compounding pharmacies may prepare it.

503B outsourcing facilities face a different question. Under 503B, a facility may only compound using bulk drug substances that appear on the FDA's "nominated and evaluated" 503B bulk list or that are components of an approved drug. FDA has not yet placed sermorelin on the final affirmative 503B bulk list, which means 503B outsourcing facilities operate in a regulatory gray zone with sermorelin and should obtain current guidance before compounding at scale [3].

The FDA Bulk Drug Substances List and Sermorelin

The FDA maintains two relevant lists for compounders:

• Category 1 (503A): Bulk substances that may be used in compounding because they meet USP/NF standards or have been evaluated and approved for the list.
• Category 1 (503B): Bulk substances formally evaluated and permitted for outsourcing facilities.

Sermorelin appears as a USP-recognized substance, which supports its use by 503A pharmacies. For 503B facilities, the FDA has published guidance indicating that substances nominated but not yet placed on the affirmative 503B list may not be compounded in bulk by outsourcing facilities absent further FDA action [3]. Patients and prescribers should confirm with their pharmacy whether it operates under 503A or 503B licensure.

Ohio State Law: What the State Actually Controls

Ohio Revised Code and the Board of Pharmacy

Ohio does not have a standalone sermorelin statute. The Ohio State Board of Pharmacy (OSBP) oversees all compounding activity under Ohio Revised Code (ORC) Chapter 4729 and administrative code OAC 4729-16, which largely mirrors and incorporates the federal 503A/503B framework [4]. A pharmacy compounding sermorelin in Ohio must hold a valid Ohio compounding license and comply with USP Chapter 797 sterile compounding standards, because sermorelin is administered by subcutaneous injection.

The OSBP has the authority to discipline a pharmacy that dispenses a compounded drug without a valid patient-specific prescription or that violates sterile compounding standards. The board does not, however, maintain a separate state-level list of banned peptides distinct from FDA guidance.

Ohio Medical Practice Act and Prescribing Authority

Under ORC 4731, any physician (MD or DO), advanced practice registered nurse (APRN) with prescriptive authority, or physician assistant (PA) with a valid collaborating agreement may prescribe sermorelin in Ohio [5]. There is no special state registration or permit required beyond standard DEA registration (needed for controlled substances, which sermorelin is not) and an active Ohio license.

The Medical Practice Act does require that prescribing occur within a valid prescriber-patient relationship. "Valid" means the prescriber has performed or arranged for an appropriate evaluation, established a diagnosis or clinical rationale, and documented the prescription in a medical record. Prescribing sermorelin solely on the basis of a brief online questionnaire with no clinical review would violate Ohio's standard-of-care expectations.

Telehealth Prescribing in Ohio

Ohio's telehealth statute, ORC 4731.296, explicitly permits prescribing via synchronous audio-video telehealth visits, provided the prescriber holds an active Ohio license or an out-of-state license with Ohio reciprocity [5]. This means a patient in Columbus or Cleveland can receive a sermorelin prescription from a telehealth provider without an in-person visit, so long as the visit meets the standard-of-care criteria above. Prescribing via asynchronous text alone (without a live encounter) may not satisfy Ohio's standard-of-care requirements for a new controlled or compounded medication.

Is Sermorelin a Controlled Substance in Ohio?

No. Sermorelin does not appear on the DEA's Schedule I through V list under the Controlled Substances Act, nor does Ohio list it as a Schedule VI substance under ORC 3719 [6]. It is not analogous to a scheduled anabolic steroid; it is a peptide analogue of a naturally occurring hormone rather than an androgenic compound.

Growth hormone itself (somatropin) is a Schedule III controlled substance under federal law [6]. Sermorelin is not growth hormone. It is a secretagogue that stimulates the pituitary to release endogenous GH. That functional and chemical distinction is why it falls outside scheduling, though it still requires a prescription as a compounded drug.

Clinical Context: Why Physicians Prescribe Sermorelin

Growth Hormone Deficiency and Adult GH Decline

GH secretion declines approximately 14% per decade after age 30 [7]. Adult GH deficiency (AGHD), when formally diagnosed by stimulation testing, is associated with reduced lean mass, increased visceral fat, poor sleep quality, and reduced quality of life. The 2019 Endocrine Society Clinical Practice Guideline on AGHD states: "We recommend GH replacement in adults with GH deficiency to normalize body composition, bone density, and quality of life" [8].

Sermorelin provides an alternative approach by stimulating endogenous GH release through GHRH receptor agonism rather than exogenous GH replacement. Because the pituitary still controls the release, sermorelin preserves a natural pulsatile GH pattern, which may reduce the risk of supraphysiologic GH levels compared with direct GH injections.

Evidence Base for Sermorelin

The original Phase III data supporting Geref's approval showed statistically significant increases in IGF-1 levels and growth velocity in GH-deficient children [1]. Adult data are thinner. A randomized, double-blind trial by Vittone et al. (N=89) found that sermorelin acetate 2 mg/night for 6 months increased mean IGF-1 by 30% and improved sleep quality scores compared with placebo (P<0.01) [9]. A smaller study by Corpas et al. (N=21) demonstrated that twice-daily subcutaneous sermorelin 0.5 mg increased pulsatile GH amplitude by 60% versus baseline at 6 months [10].

These are not large Phase III outcomes trials. Prescribers should discuss the evidence limitations with patients and document informed consent.

Typical Dosing Protocol

Most compounding pharmacies dispense sermorelin in vials of 3 mg to 15 mg. A commonly prescribed starting dose in adults is 0.2 to 0.3 mg (200 to 300 mcg) by subcutaneous injection at bedtime, titrated over 4 to 8 weeks based on IGF-1 response. Cycles commonly run 3 to 6 months, followed by a 4 to 8-week off period. These parameters are not FDA-approved dosing guidelines but represent standard clinical practice drawn from the prescribing patterns in the Vittone and Corpas trials [9, 10].

How to Get Sermorelin Legally in Ohio

Step 1: Consult a Licensed Ohio Prescriber

The first requirement is a consultation with a physician, APRN, or PA licensed in Ohio. The consultation should include a review of symptoms, a physical or telehealth examination, and baseline labs. Most clinicians order a morning IGF-1 level and a comprehensive metabolic panel before prescribing.

Step 2: Obtain Baseline Laboratory Testing

Standard labs before sermorelin initiation include:

• Serum IGF-1 (age- and sex-adjusted reference ranges from the prescribing lab)
• Fasting glucose and HbA1c (sermorelin may transiently affect insulin sensitivity)
• Thyroid panel (TSH, free T4), since hypothyroidism blunts GH response
• Comprehensive metabolic panel

Results guide whether a trial is appropriate and establish a baseline for monitoring at 3 months.

Step 3: Pharmacy Verification

The prescriber sends the prescription to a licensed 503A compounding pharmacy. Patients in Ohio can use an in-state Ohio-licensed compounding pharmacy or an out-of-state 503A pharmacy licensed to ship into Ohio. The pharmacy must compound sermorelin under USP Chapter 797 sterile conditions. Patients should ask the pharmacy for its PCAB accreditation status or state inspection records as a quality check.

Step 4: Injection Training and Follow-Up

Sermorelin is a subcutaneous injection. Most telehealth providers deliver an instruction video or schedule a live training call. Follow-up labs (repeat IGF-1) are standard at 8 to 12 weeks. The prescriber should confirm IGF-1 remains within the age-adjusted reference range; levels consistently above 250 ng/mL in adults over 40 signal possible over-treatment.

Risks of Obtaining Sermorelin Outside Legal Channels

Sermorelin sold by overseas peptide research companies, gray-market "research chemical" vendors, or websites that do not require a prescription is illegal to purchase for human use in the United States. Such products are not manufactured under FDA oversight, may contain incorrect peptide sequences, and have no verified sterility. The FDA has issued multiple warning letters to peptide vendors marketing research peptides for human use without an approved NDA or valid compounding exemption [11].

Ohio patients who purchase sermorelin this way risk receiving an adulterated or mislabeled product and have no legal recourse if harmed. The prescriber who provides a "prescription" for such a purchase without a legitimate clinical encounter may face Ohio Medical Board disciplinary action under ORC 4731.22 [5].

The table below summarizes the legal pathways at a glance.

| Source | Legal in Ohio? | Requires Rx? | FDA Oversight? | |---|---|---|---| | Ohio 503A compounding pharmacy | Yes | Yes | Yes (USP 797, state board) | | Out-of-state 503A pharmacy shipping to Ohio | Yes | Yes | Yes | | 503B outsourcing facility (sermorelin) | Gray area; confirm with FDA guidance | Yes | Partial (503B list pending) | | Research chemical website | No | No | None | | Overseas online vendor | No | No | None |

Ohio-Specific Enforcement and Compliance Notes

The Ohio State Board of Pharmacy conducts routine and complaint-driven inspections of compounding facilities. Pharmacies that dispense compounded sterile products without a valid patient-specific prescription, or that fail USP Chapter 797 sterility standards, face license suspension. The OSBP's 2023 annual report documented 14 enforcement actions against compounding pharmacies, none specifically for sermorelin but several for sterile compounding failures that could affect any injectable peptide product [4].

Ohio physicians face potential Medical Board discipline if they prescribe sermorelin without an appropriate clinical workup, particularly if the prescription is issued to a patient who has not been evaluated for active malignancy. The Endocrine Society guideline notes that GH-axis stimulation is contraindicated in patients with active malignancy, and the same caution applies to sermorelin [8].

Key Takeaways for Ohio Patients and Prescribers

Sermorelin is legal in Ohio. A valid Ohio prescription, filled by a licensed 503A compounding pharmacy, is the compliant path. The regulatory complexity lies in the FDA's compounding framework, not in any Ohio-specific prohibition. 503B outsourcing facilities should obtain updated FDA guidance before including sermorelin in their formularies, given the pending status of the 503B bulk substances list.

Prescribers should document a clinical indication, baseline IGF-1, and informed consent. Follow-up IGF-1 at 8 to 12 weeks with a target in the age-adjusted mid-normal range (typically 100 to 250 ng/mL for adults over 40) is the standard monitoring interval most clinicians apply based on the Corpas dosing data [10].